BACKGROUND: Conversion of factor XI (FXI) to FXIa is enhanced by polymers of inorganic phosphate (polyP). This process requires FXI to bind to polyP. Each FXIa subunit contains anion-binding sites (ABSs) on the apple 3 (A3) and catalytic domains that are required for normal heparin-mediated enhancement of FXIa inhibition by antithrombin. AIMS: To determine the importance of FXI ABSs to polyP enhancement of FXI activation. METHODS: Recombinant FXI variants lacking one or both ABSs were tested in polyP-dependent purified protein systems, plasma clotting assays, and a murine thrombosis model. RESULTS: In the presence of polyP, activation rates for FXI lacking either ABS were reduced compared with wild-type FXI, and FXI lacking both sites had an even greater defect. In contrast to heparin, polyP binding to FXIa did not enhance inhibition by antithrombin and did not interfere with FXIa activation of FIX. FXI lacking one or both ABSs does not reconstitute FXI-deficient plasma as well as wild-type FXI when polyP was used to initiate coagulation. In FXI-deficient mice, FXI lacking one or more ABSs was inferior to wild-type FXI in supporting arterial thrombus formation. CONCLUSIONS: The ABSs on FXIa that are required for expression of heparin's cofactor activity during protease inhibition by antithrombin are also required for expression of polyP cofactor activity during FXI activation. These sites may contribute to FXI-dependent thrombotic processes.
BACKGROUND: Conversion of factor XI (FXI) to FXIa is enhanced by polymers of inorganic phosphate (polyP). This process requires FXI to bind to polyP. Each FXIa subunit contains anion-binding sites (ABSs) on the apple 3 (A3) and catalytic domains that are required for normal heparin-mediated enhancement of FXIa inhibition by antithrombin. AIMS: To determine the importance of FXIABSs to polyP enhancement of FXI activation. METHODS: Recombinant FXI variants lacking one or both ABSs were tested in polyP-dependent purified protein systems, plasma clotting assays, and a murinethrombosis model. RESULTS: In the presence of polyP, activation rates for FXI lacking either ABS were reduced compared with wild-type FXI, and FXI lacking both sites had an even greater defect. In contrast to heparin, polyP binding to FXIa did not enhance inhibition by antithrombin and did not interfere with FXIa activation of FIX. FXI lacking one or both ABSs does not reconstitute FXI-deficient plasma as well as wild-type FXI when polyP was used to initiate coagulation. In FXI-deficientmice, FXI lacking one or more ABSs was inferior to wild-type FXI in supporting arterial thrombus formation. CONCLUSIONS: The ABSs on FXIa that are required for expression of heparin's cofactor activity during protease inhibition by antithrombin are also required for expression of polyP cofactor activity during FXI activation. These sites may contribute to FXI-dependent thrombotic processes.
Authors: A Brill; T A Fuchs; A S Savchenko; G M Thomas; K Martinod; S F De Meyer; A A Bhandari; Denisa D Wagner Journal: J Thromb Haemost Date: 2012-01 Impact factor: 5.824
Authors: Stephanie A Smith; Sharon H Choi; Julie N R Collins; Richard J Travers; Brian C Cooley; James H Morrissey Journal: Blood Date: 2012-09-11 Impact factor: 22.113
Authors: Shashank Jain; George A Pitoc; Eda K Holl; Ying Zhang; Luke Borst; Kam W Leong; Jaewoo Lee; Bruce A Sullenger Journal: Proc Natl Acad Sci U S A Date: 2012-07-25 Impact factor: 11.205
Authors: Yipeng Geng; Ingrid M Verhamme; Stephen B Smith; Mao-Fu Sun; Anton Matafonov; Qiufang Cheng; Stephanie A Smith; James H Morrissey; David Gailani Journal: Blood Date: 2013-03-20 Impact factor: 22.113
Authors: Rami A Al-Horani; Elsamani I Abdelfadiel; Daniel K Afosah; Shravan Morla; Jyothi C Sistla; Bassem Mohammed; Erika J Martin; Masahiro Sakagami; Donald F Brophy; Umesh R Desai Journal: J Thromb Haemost Date: 2019-09-10 Impact factor: 5.824
Authors: Ivan Ivanov; Ruhama Shakhawat; Mao-Fu Sun; S Kent Dickeson; Cristina Puy; Owen J T McCarty; Andras Gruber; Anton Matafonov; David Gailani Journal: Thromb Haemost Date: 2017-01-26 Impact factor: 5.249